Project title
早期診斷術後急性腎臟衰竭研究－新型生物指標，調節鐵調素HJV預測術後急性腎臟損傷
Internal ID
NSC101-2314-B002-085-MY3
Principal Investigator
Start Date
August 1, 2013
End Date
July 12, 2014
Investigators
Organizations
Partner Organizations
Project Web Site
Early diagnosis of post-operative AKI using novel biomarker :HJV predict surgery associated acute kidney injury = 早期診斷術後急性腎臟衰竭研究－新型生物指標，調節鐵調素HJV預測術後急性腎臟損傷
Keywords
HJV
Acute kidney injury
Furin
biomarker
major operation
Description
Postoperative acute renal failure is a serious complication resulting in a prolonged stay and high mortality. Acute kidney injury (AKI) develops in 5 to 30% of patients who undergo surgery, and for all causes, it is associated with mortality rates of 60–70%. Despite significant technical advances in therapeutics, the mortality and morbidity rates associated with acute kidney injury remain dismally high and have not appreciably improved during the past four decades. The serum creatinine concentration performs poorly in the setting of AKI. An ideal biomarker for acute kidney injury would help clinicians and scientists diagnose the most common form of acute kidney injury in hospitalized patients, acute tubular necrosis, early and accurately and may aid to risk-stratify patients with acute kidney injury by predicting the need for renal replacement therapy, the duration of acute kidney injury, the length of stay, and mortality. In this pioneer study we find urine soluble hemojuvelin, (HJV) elevated during AKI both in patients and mice model. Therefore, the program fall into (1) exam the signal pathway of mHJV, sHJV, SMAD/BMP pathway in human kidney tubule cell line (HK2) and restored AKI by furin inhibitor, (2) stratification the disease severity and prognosis in kinds of AKI rat models (3) validation of the HJV with reported novel biomarkers in post-operative AKI to predict patients’ outcomes. We also focus on validation the sensitivity and specificity of our newly discovered protein HJV. Therefore, this study is novel with documented preliminary data. The markers might extend the therapeutic window during which timely and individualized patient management might be possible.